The U.S. FDA’s final guidance for clinical trial inspections conducted under the bioresearch monitoring (BiMo) program seems to deviate little if at all from the 2024 draft, but that is precisely the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback